- Poster presentation and Rapid-Fire Poster Talk to feature company's second series of first-in-class NBD1 stabilizers and complementary CFTR modulators -

-海报展示和Rapid Fire海报与feature company的第二系列一流NBD1稳定器和互补CFTR调制器进行对话-

BOSTON, Oct. 18, 2023 /PRNewswire/ -- Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced that the company's data will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) to be held November 2-4 in Phoenix, Arizona..

波士顿，2023年10月18日/PRNewswire/-Sionna Therapeutics，一家致力于开发高效和差异化治疗囊性纤维化（CF）的临床阶段生命科学公司，今天宣布该公司的数据将于2023年在亚利桑那州凤凰城举行的北美囊性纤维化会议（NACFC）。。

Greg Hurlbut, Ph.D., Co-Founder and Senior Vice President, Discovery Research of Sionna, will present poster number 289, titled, 'Beyond SION-638: a novel series of highly potent stabilizers of NBD1 enable full correction of ΔF508-CFTR in a dual combination with Sionna CFTR modulators, providing a path to wild-type function,' during a poster session scheduled on Friday, November 3 from 11:40am-12:40pm MST..

SIONA发现研究的联合创始人兼高级副总裁Greg Hurlbut博士将展示289号海报，标题为“超越SION-638:NBD1的一系列高效稳定剂能够在与SIONA CFTR调制器的双重组合中完全校正ΔF508-CFTR，为野生型功能提供途径”，在周五的海报会议期间，11月3日上午11:40至12:40 MST。。

Dr. Hurlbut will also participate in a Rapid-Fire Poster Talk scheduled on Thursday, November 2 from 8:30-9:10am MST.

Hurlbut博士还将参加11月2日星期四上午8:30-9:10的MST快速火灾海报演讲。

For more information about NACFC 2023, visit https://www.nacfconference.org/.

For more information about NACFC 2023, visit https://www.nacfconference.org/.

About Sionna TherapeuticsSionna Therapeutics is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Building on over a decade of extensive research on the genetic mutations associated with CF and founded in 2019, Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ΔF508, the most common mutation that affects the CFTR protein.

关于Sionna Therapeutics Na Therapeutics是一家临床阶段生命科学公司，致力于通过标准化CFTR的功能来开发高效和分化的囊性纤维化（CF）治疗方法，CFTR是与CF疾病进展相关的关键蛋白。在十多年来广泛研究与CF相关的基因突变，成立于2019年，Sionna正在推进一系列小分子工程，以纠正由ΔF508引起的蛋白质缺陷，ΔF508是影响CFTR蛋白质的最常见突变。

The company has a first-in-class portfolio of programs directly targeting correction of NBD1, the key and unique mechanism to enable full restoration of ΔF508-CFTR function, and complementary programs targeting ICL4 and TMD1. Sionna's pipeline has the potential to deliver best-in-class efficacy and reach previously unachievable levels of long-term benefit for people with CF.

该公司拥有直接针对NBD1校正的一流程序集，NBD1是实现ΔF508-CFTR功能完全恢复的关键和独特机制，以及针对ICL4和TMD1的补充程序。Sionna的管道有可能为CF患者提供一流的疗效并达到以前无法实现的长期利益水平。

For information about Sionna visit https://www.sionnatx.com/..

For information about Sionna visit https://www.sionnatx.com/..

Media ContactAdam DaleyBerry & Company Public Relations 212.253.8881 [email protected]

媒体联系Adam DaleyBerry＆Company Public Relations 212.253.8881[受电子邮件保护]

Investor Contact [email protected]

投资者联系[电子邮件保护]

SOURCE Sionna Therapeutics

来源Sionna Therapeutics